| PRODUCT | DETAILS |
|---|---|
| Brukinsa | — |
| Tislelizumab | — |
| Pamiparib | — |
China's largest oncology biotech by revenue. Brukinsa (zanubrutinib), a next-generation BTK inhibitor, is approved in 70+ countries competing directly with AstraZeneca's Calquence and AbbVie's Imbruvica globally. Dual-listed NASDAQ (BGNE) and HKEX (6160.HK). Significant US and EU commercial presence.